



## OPEN

## Two different approaches for pharmacokinetic modeling of exhaled drug concentrations

## SUBJECT AREAS:

COMPUTATIONAL  
BIOLOGY AND  
BIOINFORMATICS

MEDICAL RESEARCH

S. Kreuer<sup>1</sup>, A. Hauschild<sup>2</sup>, T. Fink<sup>1</sup>, J. I. Baumbach<sup>3</sup>, S. Maddula<sup>4</sup> & Th. Volk<sup>1</sup>Received  
24 April 2014Accepted  
4 June 2014Published  
24 June 2014Correspondence and  
requests for materials  
should be addressed to  
S.K. ([sascha.kreuer@uks.eu](mailto:sascha.kreuer@uks.eu))

<sup>1</sup>Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine, 66482 Homburg/Saar; Germany, <sup>2</sup>Max Planck Institute for Informatics, Research Group on Computational Systems Biology, Campus E2.1, R. 203, 66123 Saarbrücken; Germany, <sup>3</sup>Reutlingen University, Faculty Applied Chemistry, Alteburgstrasse 150, 72762 Reutlingen; Germany, <sup>4</sup>B&S Analytik, BioMedicalCenter Dortmund, Otto-Hahn-Str. 15, 44227 Dortmund; Germany.


Online measurement of drug concentrations in patient's breath is a promising approach for individualized dosage. A direct transfer from breath- to blood-concentrations is not possible. Measured exhaled concentrations are following the blood-concentration with a delay in non-steady-state situations. Therefore, it is necessary to integrate the breath-concentration into a pharmacological model. Two different approaches for pharmacokinetic modelling are presented. Usually a 3-compartment model is used for pharmacokinetic calculations of blood concentrations. This 3-compartment model is extended with a 2-compartment model based on the first compartment of the 3-compartment model and a new lung compartment. The second approach is to calculate a time delay of changes in the concentration of the first compartment to describe the lung-concentration. Exemplarily both approaches are used for modelling of exhaled propofol. Based on time series of exhaled propofol measurements using an ion-mobility-spectrometer every minute for 346 min a correlation of calculated plasma and the breath concentration was used for modelling to deliver  $R^2=0.99$  interdependencies. Including the time delay modelling approach the new compartment coefficient  $k_{e0lung}$  was calculated to  $k_{e0lung}=0.27 \text{ min}^{-1}$  with  $R^2=0.96$ . The described models are not limited to propofol. They could be used for any kind of drugs, which are measurable in patient's breath.

In medicine, drug dosing is usually adapted to patient's weight. However, the blood concentration of medications varies considerably between different individuals. The blood concentration depends on the liberation, absorption, distribution, metabolism and the excretion of the drug. These factors are influenced by normal variability of the individual, genetic influences particularly in cytochrome P450 system and organ dysfunctions. These relationships are described as pharmacokinetics (PK).

Different compartment<sup>1</sup> and non-compartment PK models e.g. physiological models<sup>2</sup> are used to calculate plasma or effect concentrations of drugs. These models are based on normal population PK data sets. However, the concentrations are only calculated and the difference to the real drug blood concentration could be substantially<sup>3</sup>. The measurement of blood concentration e.g. by High-Performance Liquid Chromatography (HPLC) is expensive, complex and has a time delay of several hours. In clinical practise the measurement of blood concentrations is only performed for a few drugs<sup>4</sup>.

Therefore, a new promising approach is the online measurement of drug concentrations in patient's breath<sup>5</sup>. Until now, the number of drugs which were detected in patient's breath is limited: e.g. methadone<sup>6</sup>, propofol<sup>7</sup>, valproic acid<sup>8</sup>.

Actually, different methods are under consideration, including mass spectrometry, ion mobility spectrometry and chemical sensors. In the present paper, we will not focus on the experimental details, conditions, advantages and disadvantages of the different methods. The starting condition is, that such measurements can be carried out and time series of breath concentration values are available within short time intervals. Acceptable would be the range of one value per minute of exhaled breath concentration, with a total analysis time in the same range of 1 minute. Consequently, one value each minute with 1 minute retarding will be considered as provided by an experimental breath analysis method.



**Figure 1 | Three compartment pharmacokinetic model.**  $K_{XX}$  = rate constants for metabolism and elimination,  $V_1$  = Volume of central compartment/blood concentration,  $V_2 = V_1 * k_{12}/k_{21}$ ,  $V_3 = V_1 * k_{13}/k_{31}$ , Elimination clearance =  $V_1 * k_{10}$ , Clearance 2 =  $V_2 * k_{21}$ , Clearance 3 =  $V_3 * k_{31}$ .

However, a direct transfer between breath concentration and blood concentration is not possible and leads to poor correlation values, because the diffusion of drugs through the capillary wall of the alveoli takes time. If the drugs blood concentration increases or decreases the exhaled concentration follows with a time delay<sup>9</sup>.

Classically the diffusion of a drug from blood through the lung into air is described by the blood/gas partition coefficient (Ostwald Coefficient). This coefficient is defined as the ratio of the concentration in blood to the concentration in gas that is in contact with that blood when the partial pressure in both compartments is at equilibrium. It is thus a dimensionless number. The higher the blood/gas partition coefficient, the more soluble is the anaesthetic in blood compared to air and the more it binds to lipids and proteins in the blood. If an anaesthetic has a high Ostwald coefficient, then a large amount of it will have to be taken up in the body's blood before being passed on to the fatty (lipid) tissues of the brain where it can exert its effect<sup>10</sup>.

The blood/gas partition coefficient is widely used for the PK description of volatile anaesthetics<sup>10</sup>. However, for PK modelling the coefficient could only be used if the partial pressure in both compartments is at equilibrium. Depending on the drug it could take several hours to reach this steady state. Therefore, the introduction of breath concentrations measured within time series needs a model to include the concentration values measured in breath without the precondition of compartments within equilibrium.

To overcome the precondition of equilibrium, we would like to demonstrate in this manuscript two different PK modelling approaches to handle the drug breath concentrations. The calculations are performed on the basis of concentration data of the measurements of a patient, who received the intravenous anaesthetic propofol. The propofol breath concentration was measured by a modified ion mobility spectrometer combined with a multicapillary-column (P-IMS)<sup>11</sup>, which delivers one peak analysis every minute with 1 minute total analysis time including sampling of 10 mL exhaled breath. It should be noted, that the presented models are not specific for propofol. In principle, the mathematical descriptions could also be used for other drugs.

## Methods

**Clinical measurements.** With approval of the local Ethics Committee (Ärztchamber des Saarlandes, Saarbrücken, Germany) and written informed consent an adult patient scheduled for an abdominal surgical procedure was studied. The patient received propofol and remifentanyl (opioid) as a target controlled infusion (TCI). The concept of TCI is to estimate calculated plasma and effect site concentrations based on pharmacokinetic 3 compartment model<sup>12</sup>.

The breath concentration values were measured using an ion mobility spectrometer type BioScout (B&S Analytik GmbH, Dortmund, Germany), with the internal

Multi-capillary-column (MCC) adjusted to 90 °C to reach a retention time of propofol on the MCC (type OV-5, Multichrom, Novosibirsk, Russia) of about 20 s. A total volume of 10 mL was taken on the MCC. For further details considering the method see<sup>11</sup>, for the experimental setup see<sup>13</sup>. Samples of exhaled air were automatically taken every minute by the P-IMS.

A typical pharmacokinetic model including 3 compartments is shown in Figure 1. Here,  $V_1$  represents the central blood compartment, the other 2 compartments named  $V_2$  and  $V_3$  are considered as an additional fast and another slow metabolizing compartment. Therefore, the incoming intravenous drug (i.v.) will go with the reaction coefficient  $k_{10}$  out of the body (elimination) and with e.g.  $k_{13}$  from  $V_1$  to  $V_3$  and  $k_{31}$  from  $V_3$  back to  $V_1$ , respectively. The clearance of the central compartment is described as  $V_1 * k_{10}$  and the concentration in compartment  $V_3$  is represented by the value  $V_3 = V_1 * k_{13}/k_{31}$ . Thus, the clearance 2 is  $V_2 * k_{21}$ .

For the administration of propofol we used the Marsh data set<sup>14</sup> with a constant target concentration of 3 µg/ml in compartment  $V_1$ . The corresponding values of  $V_1$  and the reaction coefficients are shown in Table 1. Here, following to the Marsh model,  $V_1$  is calculated with the weight of the patient multiplied with 0.228 (Table 1).

The major disadvantage of TCI is that the concentrations are only calculated and may have a deviation of about 25%<sup>3</sup> in healthy patients. The remifentanyl target concentration (Minto, plasma mode)<sup>15</sup> was adjusted to clinical needs.

**Pharmacokinetic modeling.** Plotting the exhaled propofol concentration versus the calculated propofol plasma concentration revealed a hysteresis loop (see below). Therefore, it is necessary to include the measured propofol concentration into a pharmacokinetic model.

Two different approaches for kinetic modelling were tried. First the 3-compartment model was extended. We calculated an additional 2-compartment model based on the first compartment of the Marsh model and a new lung compartment  $V_{Lung}$  (Fig. 2).

For the relationship between exhaled propofol concentration and the respective propofol lung concentration values a polynomial second order was used.  $V_{Lung}$ ,  $CL_{Lung}$  and the parameters of the polynomial second order were estimated using nonlinear regression with ordinary least squares.


The computations were performed on a spreadsheet using the Excel 2010 software program (Microsoft). The parameters were optimized to maximise  $R^2$  using the Solver tool within Excel.

The second approach was to calculate a time delay of the plasma concentration dependent to the measurements of exhaled propofol concentrations as a first order model (Fig. 3). The computation was performed in the same way as described above.

Concentrations measured with the IMS are given as intensities in volt. Usually concentrations in this range are given as parts per billion [ppb]. The transfer from volt to ppb was performed with a calibration curve. Therefore, the modelling of both

**Table 1 | Marsh data set<sup>14</sup> (m is the weight of the patient expressed in kg)**

$V_1$	0,228*m [kg]
$k_{10}$	0,1190
$k_{12}$	0,1140
$k_{21}$	0,0550
$k_{13}$	0,0419
$k_{31}$	0,0033



**Figure 2** | 3-compartment pharmacokinetic model extended with an additional lung compartment with a volume ( $V_{Lung}$ ) and clearance ( $Cl_{Lung}$ ).  $LCC = (k_{1L} * PPCO - k_{L1} * LCCO) + LCCO$ .  $LCC$  = Lung compartment concentration,  $k_{1L} = Cl_{Lung}/V_1$ ,  $PPCO$  = Previous Propofol plasma concentration,  $k_{L1} = V_{Lung}/Cl_{Lung}$ ,  $LCCO$  = Previous lung compartment concentration,  $V_1$  = Volume first compartment marsh model ( $= 0,228 * \text{patient weight } m \text{ [kg]}$ ).  $V_{Lung}$  = Volume lung compartment,  $Cl_{Lung}$  = Clearance lung compartment.

approaches was done two times for volt and ppb. A difference occurs due to the non-linear response of the ion mobility spectrometer within the calibration curve.

## Results


The P-IMS was tested in patients under clinical conditions in the operation room. To demonstrate the mathematical PK/PD modeling approaches data from one patient were used. The duration of this measurement was 346 min. We were able to perform one measurement each minute. There was no technical failure of the P-IMS hardware or software. During induction of anaesthesia the exhaled propofol concentration increased with a time delay compared to the TCI plasma concentration. During the maintenance of anaesthesia, the exhaled propofol concentration increased continuously. The propofol TCI target plasma concentration was set stable at  $3 \mu\text{g/ml}$ . At the end of the surgical procedure the propofol TCI administration was stopped. The exhaled propofol concentration decreased with a small time delay (Fig. 4).

**PK-Modeling.** Plotting the propofol breath concentration peak intensity [volt a) or [ppb b) versus calculated propofol plasma concentration revealed a hysteresis loop (Fig. 5).


Figure 5 indicates that a direct correlation analysis between plasma concentrations and exhaled concentrations is not useful. These calculations lead to poor  $R^2$  values ( $R^2 = 0,32$  [volt];  $R^2 = 0,41$  [ppb]).

**Propofol lung compartment concentration.** The hysteresis loop collapsed by introduction of the propofol lung compartment concentration or a time delay of the propofol plasma concentration (Fig. 6/ Fig. 7).

Using the measured breath concentration in ppb the propofol lung compartment of this individual patient could be described by a volume of 17 L and a clearance of 3,75 L/min. The rate constants were  $k_{1L} = 0,209 \text{ min}^{-1}$  and  $k_{L1} = 0,138 \text{ min}^{-1}$ . Using these parameters for calculation the lung compartment concentration yielded



**Figure 3** | Three compartment pharmacokinetic model the propofol lung concentration is calculated from the blood concentration with a time delay.  $LCC = (PPC + (LCCO - PPC)) * \exp(-k_{e0Lung} * t)$ ,  $PPC$  = Propofol plasma concentration,  $k_{e0Lung}$  = First-order rate constant determining the equilibration between plasma, and lung concentration.



**Figure 4 | Time course.** Time course of the calculated propofol TCI concentration (blue line) and the measured P-IMS breath concentration (red line concentration [ppb], green line peak height [volt]) over 346 min.

into a correlation coefficient of  $R^2=0.99$  (Fig. 6b). The polynomial second order is given by:

$$y = -5.9x^2 + 9.23x + 0,$$

where  $y$  is the lung compartment concentration and  $x$  the propofol breath concentration.

The correlation value is lower using the original intensity values given in volt ( $R^2=0.87$ ) (Fig. 6a).

$$y = -12.6x^2 + 15.57x + 0,$$

where  $y$  is the lung compartment concentration and  $x$  the propofol peak intensity.

**Time delay of the propofol plasma concentration.** The time delay pharmacokinetic modeling approach results into a lower correlation

coefficient  $R^2=0.96$  than using an additional compartment for describing the lung propofol concentration (Fig. 7).


The correlation between the model and measurements in ppb is  $R^2=0.96$  (Fig. 7b).

$$y = -4.2x^2 + 7.14x + 0,$$


where  $y$  is the lung compartment concentration and  $x$  the propofol concentration.

The propofol lung plasma time delay concentration of this individual patient was calculated with a first-order rate constant determining the equilibration between plasma and lung concentration  $k_{e0lung} = 0.27 \text{ min}^{-1}$ .

The correlation value is lower using the original intensity values given as peak height measured in volt ( $R^2 = 0.82$ ) (Fig. 7a).



**Figure 5 | Hysteresis loop between plasma concentration and breath concentration.** Calculated propofol plasma concentration versus breath concentration measured by the P-IMS (a) green dots: peak height; [volt]; (b) red dots: concentration [ppb].



**Figure 6 | Propofol lung compartment concentration.** The dots are the measured propofol concentration (a) green dots: peak height [volt]), (b) red dots: concentration [ppb] versus the propofol lung compartment concentration in  $\mu\text{g/ml}$ . The blue line is the polynomial second order.

$$y = -7.7x^2 + 9.64x + 0,$$


where  $y$  is the lung compartment concentration and  $x$  the propofol peak intensity.

## Discussion

In this manuscript two different pharmacological models are presented for the description of the pharmacokinetic of exhaled drug concentrations. The calculations were exemplarily performed for propofol, an intravenous anaesthetic widely used in clinical practice. The exhaled propofol concentration was measured with a modified MCC/IMS (P-IMS).

Under clinical conditions it is not possible to measure the propofol blood concentration online. Therefore, computer-assisted infusion pumps (Target controlled infusion (TCI)) were developed to calculate the propofol blood concentration based on the demographic patient data and the dosage<sup>12</sup>. A 3-compartment pharmacokinetic model is used for the calculation of the blood concentration. This

blood or plasma concentration is given in the first compartment V1. Our first PK modeling approach is to extend this 3-compartment model for another 2-compartment model. The first compartment V1 is used parallel for both models. The second compartment of the 2-compartment model represents the lung compartment. The lung compartment has a volume ( $V_{\text{Lung}}$ ). The volume is given in liters (L). The value is a virtual volume of distribution and not physiologically. The second parameter is the clearance of the compartment given in L/min ( $CL_{\text{Lung}}$ ). Both values are used to calculate rate constants for metabolism and elimination. We have named these constants as  $k_{1L}$  and  $k_{L1}$ .  $k_{L1}$  is the deviation of the volume of the lung compartment and clearance of the lung compartment.  $k_{1L}$  is required to balance the drug concentration between the lung compartment and the blood compartment. This PK approach has to be used if the drug is metabolized by the lung or if the drug accumulates in the lung. If there a metabolism of the drug in the lung the clearance value is positive. The clearance value is negative, if an accumulation is pre-



**Figure 7 | Time delay of the propofol plasma concentration.** The dots are the measured propofol concentration (a) green dots: peak height [V], (b) red dots: concentration [ppb] versus the propofol lung plasma time delay concentration in  $\mu\text{g/ml}$ . The blue line is the polynomial second order.



sent. For propofol there are some publications from animal studies, hypothesizing that propofol is metabolized by the lung<sup>16</sup>.

Our second approach could be used, if there is only a time delay between changes of the drug concentration and exhaled concentrations. This PK model excludes changes of the concentration by the lung itself. The equilibration between plasma and lung concentration is described by a first-order rate constant ( $k_{e0}$ ). The  $k_{e0}$  value describes the time delay between changes of the blood concentration of anaesthetics and their effect at the brain measured with the EEG<sup>17</sup>. The transition of anaesthetics across the blood–brain barrier needs a certain time. The effects of anaesthetics on the brain can be measured with an EEG monitor<sup>18</sup>.

Then this method was transferred to describe the time delay between changes of the measured end-tidal concentration of volatile anaesthetics and the EEG effect<sup>19</sup>. Equilibration between end-tidal and brain concentrations of volatile anaesthetics is reached after a time delay that is substance-specific and called hysteresis, i.e. the delay between the maximum plasma concentration and the maximum EEG effect. In PK/PD models this hysteresis is considered by inclusion of a fictitious compartment, the so called “effect compartment”.

We used this mathematical procedure now to describe a time delay between changes of the drug blood concentrations and the exhaled concentrations. To distinguish between the “traditional”  $k_{e0}$  value<sup>10</sup> and the new approach we introduced the term  $k_{e0\text{lung}}$ . In generally, the higher the value of  $k_{e0\text{lung}}$ , the shorter the time of equilibration between exhaled and blood concentration.

In our sample calculation for propofol both methods were suitable to describe the pharmacokinetic of the exhaled propofol concentration.

We used a polynomial of second order as a function for the PK model. For other drugs or biomarkers a linear correlation analysis could be sufficient. In other cases it could be necessary to choose a polynomial of a higher degree or a different mathematical model.

The calculations were performed for one individual patient. For one patient PK modeling could be done within Excel using the solver tool to optimize the correlation between the pharmacology model and measurements. For further analysis data of several patients in one step a Bayesian probability calculation is necessary<sup>19</sup>. The presented PK modeling methods are suitable for the continuous application of a drug. In principle they could also be used for a single bolus application.

The pharmacological principles demonstrated for propofol in this manuscript could be transferred to other medications. For propofol, further studies including measured propofol blood concentrations are necessary to build a PK model, which could be transferred into clinical practice.

Online measurement of drug concentrations in patient’s breath is a new promising approach for individualized dosage of medications. Unfortunately there is no direct correlation between exhaled and blood concentration of the drug. Therefore pharmacokinetic modelling is necessary for research and clinical practice.

- Barakat, A. R., Sutcliffe, N. & Schwab, M. Effect site concentration during propofol TCI sedation: a comparison of sedation score with two pharmacokinetic models. *Anaesthesia*. **62**, 661–666 (2007).
- Eissing, T. *et al.* A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. *Front Physiol*. **24**, 2–4 (2011).
- Glen, J. B. & Servin, F. Evaluation of the predictive performance of four pharmacokinetic models for propofol. *Br J Anaesth*. **102**, 626–632 (2009).

- Tszyrsznic, W. *et al.* Two rapid ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay. *J Chromatogr B Analyt Technol Biomed Life Sci*. **928**, 9–15 (2013).
- Berchtold, C., Bosilkovska, M., Daali, Y., Walder, B. & Zenobi, R. Real-time monitoring of exhaled drugs by mass spectrometry. *Mass Spectrom*. **22**, doi: 10.1002/mas.21393. (2013).
- Beck, O., Sandqvist, S., Eriksen, P., Franck, J. & Palmkog, G. Determination of methadone in exhaled breath condensate by liquid chromatography- tandem mass spectrometry. *J Anal Toxicol* **35**, 129–133 (2011).
- Perl, T. *et al.* Determination of serum propofol concentrations by breath analysis using ion mobility spectrometry. *Br J Anaesth* **103**, 822–827 (2009).
- Gamez, G. *et al.* Real-time, in vivo monitoring and pharmacokinetics of valproic acid via a novel biomarker in exhaled breath. *Chem Commun* **47**, 4884–4886 (2011).
- Lu, C. C. *et al.* Pharmacokinetics of sevoflurane uptake into the brain and body. *Pharmacology*. **69**, 132–137 (2003).
- Kreuer, S., Bruhn, J., Wilhelm, W. & Bouillon, T. Pharmacokinetic pharmacodynamic models for inhaled anaesthetics. *Anaesthesist*. **56**, 538–556 (2007).
- Kreuder, A. E. *et al.* Characterization of propofol in human breath of patients undergoing anesthesia. *Int. J. Ion Mobil. Spec.* **14**, 167–175 (2011).
- Schraag, S., Kreuer, S., Bruhn, J., Frenkel, C. & Albrecht, S. Target-controlled infusion (TCI) - a concept with a future?: state-of-the-art, treatment recommendations and a look into the future. *Anaesthesist*. **57**, 223–230 (2008).
- Buchinger, H. *et al.* Minimal retarded Propofol signals in human breath using ion mobility spectrometry. *Int. J. Ion Mobil. Spec.* **16**, 185–190 (2013).
- Marsh, B., White, M., Morton, N. & Kenny, G. N. Pharmacokinetic model driven infusion of propofol in children. *Br J Anaesth*. **67**, 41–48 (1991).
- Minto, C. F., Schnider, T. W. & Shafer, S. L. Pharmacokinetics and pharmacodynamics of remifentanyl. II. Model application. *Anesthesiology*. **86**, 24–33 (1997).
- Matot, I., Neely, C. F., Katz, R. Y. & Neufeld, G. R. Pulmonary uptake of propofol in cats. Effect of fentanyl and halothane. *Anesthesiology*. **78**, 1157–1165 (1993).
- Kreuer, S., Wilhelm, W., Grundmann, U., Larsen, R. & Bruhn, J. Narcotrend index versus bispectral index as electroencephalogram measures of anesthetic drug effect during propofol anesthesia. *Anesth Analg*. **98**, 692–697 (2004).
- Ellerkmann, R. K., Soehle, M. & Kreuer, S. Brain monitoring revisited: what is it all about? *Best Pract Res Clin Anaesthesiol*. **27**, 225–233 (2013).
- Kreuer, S. *et al.* Comparative pharmacodynamic modeling of desflurane, sevoflurane and isoflurane. *J Clin Monit Comput*. **23**, 299–305 (2009).

## Acknowledgments

A.H. is grateful for financial aid provided by the International Max Planck Research School, Saarbrücken, Germany. Part of the work of this paper has been supported by the Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research Center (Sonderforschungsbereich) SFB 876 Providing Information by Resource-Constrained Analysis, project TBI Resource-Constrained Analysis of Spectrometry Data (JIBB). The clinical study has been supported by Fresenius Kabi (Bad Homburg, Germany).

## Author contributions

S.K., T.V. and J.I.B. wrote the manuscript. S.K. developed the pharmacokinetic models. S.K., S.M., A.H. prepared the excel sheet for the calculation. T.F. performed the patient measurement and prepared figures 1–3. All authors reviewed the manuscript.

## Additional information

**Competing financial interests:** Patent applications for the measurement of exhaled propofol (J.I.B.; S.K.; T.V.). Related to the present pharmacokinetic models there are no financial interests.

**How to cite this article:** Kreuer, S. *et al.* Two different approaches for pharmacokinetic modeling of exhaled drug concentrations. *Sci. Rep.* **4**, 5423; DOI:10.1038/srep05423 (2014).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>